HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 2005-0602v1 25/3/712    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, R. J. Articles by Lum, L. G. Search for Related Content PubMed PubMed Citation Articles by Lee, R. J. Articles by Lum, L. G.

TRANSLATIONAL AND CLINICAL RESEARCH

Antibody Targeting of Stem Cells to Infarcted Myocardium

^aDepartment of Medicine and Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California, USA;
^bUniversity of California Berkeley and San Francisco Joint Bioengineering Graduate Group, Berkeley/San Francisco, California, USA;
^cImmunotherapy Program, Cancer Center, Roger Williams Hospital, Department of Medicine, Boston University, Providence, Rhode Island, USA;
^dDepartment of Pediatrics, Woman and Infant's Hospital and Brown Medical School, Providence, Rhode Island, USA;
^ePanorama Research, Inc., Mountain View, California, USA

Key Words. CD34+ cells • Myocardial infarction • Bispecific antibody • Cellular therapy

Correspondence: Randall J. Lee, M.D., Ph.D., Cardiac Electrophysiology, MU East Tower, Box 1354, 500 Parnassus Avenue, San Francisco, California 94143-1354, USA. Telephone: 415-476-5708; Fax: 415-476-6260; e-mail: lee{at}medicine.ucsf.edu

Received December 1, 2005; accepted for publication November 21, 2006.
First published online in STEM CELLS EXPRESS   November 30, 2006.



Hematopoietic stem cell (HSC) therapy for myocardial repair is limited by the number of stem cells that migrate to, engraft in, and proliferate at sites of injured myocardium. To alleviate this limitation, we studied whether a strategy using a bispecific antibody (BiAb) could target human stem cells specifically to injured myocardium and preserve myocardial function. Using a xenogeneic rat model whereby ischemic injury was induced by transient ligation of the left anterior descending artery (LAD), we determined the ability of a bispecific antibody to target human CD34+ cells to specific antigens expressed in ischemic injured myocardium. A bispecific antibody comprising an anti-CD45 antibody recognizing the common leukocyte antigen found on HSCs and an antibody recognizing myosin light chain, an organ-specific injury antigen expressed by infarcted myocardium, was prepared by chemical conjugation. CD34+ cells armed and unarmed with this BiAb were injected intravenously in rats 2 days postmyocardial injury. Immunohistochemistry studies showed that the armed CD34+ cells specifically localized to the infarcted region of the heart, colocalized with troponin T-stained cells, and colocalization with vascular structures. Compared to unarmed CD34+ cells, the bispecific antibody improved delivery of the stem cells to injured myocardium, and such targeted delivery was correlated with improved myocardial function 5 weeks after infarction (p < .01). Bispecific antibody targeting offers a unique means to improve the delivery of stem cells to facilitate organ repair and a tool to study stem cell biology.

This article has been cited by other articles:

				T. C. Zhao, A. Tseng, N. Yano, Y. Tseng, P. A. Davol, R. J. Lee, L. G. Lum, and J. F. Padbury Targeting human CD34+ hematopoietic stem cells with anti-CD45 x anti-myosin light-chain bispecific antibody preserves cardiac function in myocardial infarction J Appl Physiol, June 1, 2008; 104(6): 1793 - 1800. [Abstract] [Full Text] [PDF]